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For the past two decades, great achievements have been made in cancer research of China and the majority of them were support-
ed by the National Natural Science Foundation of China (NSFC). In this article, we reviewed the funding history of NSFC in-
cluding the number of proposals, the amount of grants, distribution of supported program categories during the period of 1987 to 
2012 and the representative achievements made by continuous support of NSFC. Also, the impacts of NSFC support on discipline 
development and talent fostering were analyzed. From 1987 to 2012, a total of 8738 proposals related to cancer research were 
funded by NSFC. The percentages of the Research Program, Talent-Training Program, and the Research Environment Program 
were 61.19%, 36.32%, and 2.49%, respectively. Under the support of NSFC, cancer research in China has achieved a significantly 
rapid and balanced development in both disciplines and scientist resources.  
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National Natural Science Foundation of China (NSFC) has 
held on its policies to constantly support basic and applied 
basic research since its establishment in 1986. Programs in 
cancer research are now administrated by Division of On-
cology at Department of Health Sciences of NSFC. The 
scopes of grant support in Division of Oncology cover (1) 
cancer biology, including etiology, carcinogenesis, genetics, 
immunology, prevention, recurrence and metastasis of  
tumors, and cancer stem cells; (2) cancer clinics, including 
diagnosis, chemotherapy, radiotherapy, biotherapy, inte-
grated therapeutics, and rehabilitation (social and psycho-
logical rehabilitation); and (3) new techniques in cancer 
research. On the other hand, the discipline in Division of 
Oncology is also classified based on different human medi-
cal systems/organs. Overall the scopes of application codes 
cover nearly every aspect of cancer research with the excep-
tion of tumor epidemiology and leukemia, which are man-
aged by Division of Preventive Medicine and Division of 
Haematologic and Lymphatic System Diseases, respectively. 
1  Overview of NSFC grant support on cancer 
research   
NSFC has 3 programs integrated in the whole funding sys-
tem with different focuses, which are designated for Re-
search, Talent-Training, and Research Environment pro-
grams, respectively. From 1987 to 2012, NSFC has funded 
8738 programs in cancer research with a total sum of ap-
proximately 3 billion RMB. The number and budget of the 
funded proposals in these 3 programs over the period are 
shown in Table 1. Among the funded proposals, 61.19% 
were supported via Research Program, 36.32% via Talent-  
Training Program and 2.49% via Research Environment 
Program. There are also different subcategories of programs 
corresponding to each one of the above, and the number and 
size in oncology research for each category supported by 
NSFC from 1987 to 2012 are shown in Table 2. Importantly, 
while the total funding of NSFC has been improved gradu-
ally, the budget of NSFC and, particularly, the support for 
cancer research have been increased dramatically during the  
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Table 1  Application and funding status in oncology of NSFC in China, 1987–2012 
Program Applicant no. Funding no. Funding size (million RMB) 
Research Program 31515 5347 2085.547 
Talent-Training Program 16839 3174 813.391 
Research Environment Program         493 217 34.896 
Total 48847 8738 2933.834 
Table 2  Funding categories in oncology supported by NSFC in China, 1987–2012 
Program Funding subcategories Funding no. 
Funding size 
(million RMB) 
Research Program   
General Program 4848 1687.060 
Key Program 96 190.640 
Major Program 11 30.660 
Major Research Plan 119 118.700 
Major International Cooperation 53 35.117 
The President’s and Department Directors’ Funds 220 23.370 
Talent-Training Program 
National Science Fund for Distinguished Young Scholars (DYS) 60 80.300 
Outstanding Young Investigator Fund 9 9.000 
Young Scientists Fund 2619 533.770 
Fund for Less Developed Regions 446 146.521 
Science Fund for Creative Research Groups 7 32.800 
Joint Research Fund for Overseas Chinese Scholars in Hong Kong and Macao 11 2.200 
Joint Research Projects for Oversea Young Scientists 22 8.800 
Research Environment Program  
Special Fund for Basic Research on Scientific Instruments and Journals 156 16.171 
Programs of Joint Funds 16 17.200 
International (Regional) Cooperation and Exchange  
Hold International Academic Workshops in China 
45 1.525 
Total  8738 2933.834 
 
 
past two years (Figure 1).  
2  Breakthroughs in cancer research supported 
by NSFC 
A series of groundbreaking achievements have been made  
  
 
Figure 1  Growth of funding number and size in oncology supported by 
NSFC in China, 1987–2012. 
in cancer research under NSFC support, particularly, in the 
fields of cancer genetics and epigenetics, signal transduction, 
microRNA and tumor stem cells, tumor microenvironment, 
inflammation and tumor metastasis, tumor immunology, 
and prevention and treatment of cancer during the past 26 
years. 
(i) Cancer genetics and epigenetics.  Shang YongFeng’s 
group identified a couple of oncogenes co-regulated by es-
trogen and tamoxifen. One of the genes, PAX2, regulates the 
proliferation of endometrial cancer. They found that estro-
gen and tamoxifen promote the growth of endometrium 
cancers by upregulating PAX2 expression via relieving hy-
permethylation at the Cpg islands of its promoter region, 
which is normally observed in normal endometrial cells [1]. 
Due to his novel findings in this field, Shang was invited to 
contribute a review on the molecular mechanisms of endo-
metrial cancer induced by estrogen and tamoxifen [2]. They 
also found that lysine-specific demethylase 1 (LSD1) is an 
integral component of the Mi-2/nucleosome remodeling and 
deacetylase (NuRD) complex, which regulates several cel-
lular signaling pathways including the TGF-1 signaling 
pathway that are critically involved in cell proliferation, 
survival, and epithelial-to-mesenchymal transition (EMT). 
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Moreover, they found that LSD1 is down-regulated in 
breast carcinomas and its level of expression is negatively 
correlated with that of TGF-1. Their data provided a mo-
lecular basis for the interplay of histone demethylation and 
deacetylation in chromatin remodeling [3]. In addition, an-
other research group led by Zhan QiMin identified NLP 
gene and demonstrated that it is associated with the onset of 
breast cancers in a transgenic mouse model [4].  
In search of tumor susceptibility genes, breakthroughs 
have been made in nasopharyngeal carcinoma (NPC), 
esophagus and liver cancers, which have obvious topologi-
cal distribution and are highly incident in China. Zeng 
YiXin’s group discovered the mode of inheritance of NPC 
in Guangdong families and identified a susceptibility locus 
on 4 section 2 to 5 in region 1 of the short arm of chromo-
some 4 [5], and recently, they also revealed 3 new risk loci 
of NPC on chromosomes 3, 9 and 13, and confirmed the 
known locus on chromosome 6, using a genome-wide asso-
ciation study with large scale of NPC cases and controls [6]. 
Lin DongXin’s team identified several new and functional 
variations that are associated with susceptibility to multiple 
cancer including lung, esophagus, and gastric cancer [7–9]. 
They revealed 3 new susceptibility loci for esophageal 
squamous-cell carcinoma and identified 5 new susceptibility 
loci for pancreatic cancer in Chinese populations by ge-
nome-wide association study [10].  
(ii) Signal transduction in cancer.  Wang HongYang’s 
group showed that the expression of p28GANK may serve 
as a molecular marker for diagnosis of liver cancer, and that 
p28GANK may tip the balance of proliferation and apopto-
sis of hepatoma cell by regulating the phosphorylation and 
expressive level of tumor suppressors, including RB1. 
Moreover, they found that the alpha subunit of ciliary’s 
neurotrophic factor receptor can activate both PI3K/Akt and 
MAPK signal transduction pathways upon engagement by 
ciliary’s neurotrophic factor, which contributes to the gly-
cometabolism process of normal hepatocytes and hepato-
carcinoma cells [11,12]. In the field of breast cancers, 
Zhang XueMin’s team made remarkable progress to eluci-
date the mechanism of tamoxifen-resistance of breast cancer. 
They identified a new protein, CUE-domain-containing 
protein (CUEDC2), which reduces sumoylation of proges-
terone receptor. Simultaneously, CUEDC2 serves as an 
adaptor protein to deactivate IKK by recruiting PP1 to the 
complex and thus targets IKK for dephosphorylation and 
inactivation, which contributes to the resistance of breast 
cancer cells to tamoxifen. They also found that over-   
expression of CUEDC2 is associated with poor outcome of 
breast cancer patients and may thus serve as a potential new 
target to reverse the resistance to tamoxifen. Further study 
revealed that CUEDC2 is a key regulator of mitosis pro-
gression, and its dysregulation may favor tumor develop-
ment due to chromosomal instability [13–16].   
(iii) Tumor related miRNAs and tumor stem cells.  By 
profiling the microRNAs, Song ErWei’s group demonstrat-
ed the differential expression of some small non-coding 
RNAs in breast cancer stem cells, also named breast tumor 
initiating cells, versus non breast cancer stem cells. More 
importantly, reduction in let-7 miRNA helps to maintain the 
self-renewal capacity, undifferentiation state and highly 
tumorigenic potential of breast cancer stem cells. Ectopic 
expression of the microRNA retards tumor growth in im-
munocompromised mice and inhibits breast cancer metasta-
sis. The study proposed an innovative theory that miRNA 
are crucial to the growth and metastasis of tumors by regu-
lating cancer stem cells, which is a milestone breakthrough 
in the field of tumor related miRNA and cancer stem cells 
with citation of nearly 500 times within 5 years [17]. Be-
sides, Wang HongYang’s team found that the gene locus 
harboring miR-151 is amplified at a high frequency in 
hepatocarcinoma genome leading to high expressive level 
of miR-151 in hepatocarcinoma. The overexpressed miR- 
151 silences a tumor suppressor RhoGDIA and thus pro-
motes metastasis of liver cancers [18].  
(iv) Tumor microenvironment, inflammation and tumor 
metastasis.  In studies of tumor microenvironment, Song 
ErWei’s team demonstrated that CCL18 produced by tu-
mor-associated macrophages in breast cancers is associated 
with metastasis and poor clinical outcome via promoting 
cancer cell invasion and adhesion. Furthermore, they identi-
fied that PITPNM3 is a potential functional receptor for 
CCL18. The study, published as a featured article in Cancer 
Cell, was highlighted by Nature. Song ErWei’s finding shed 
new light on the role of chemokines in cancer, and CCL18 
may serve as a potential therapeutic targets for breast cancer 
[19].  
After 10 years of hard work, Tang ZhaoYou’s team has 
established a series of models to study metastasis of liver 
cancers, which include a highly metastatic hepatoma xeno-
grafting model inoculated in nude mice, a pair of hepatoma 
cell lines MHCC97H and MHCC97L with identical cellular 
genetic background but different metastatic potentials and 
cell lines HCCLM3 and HCCLM6 with progressively in-
creased metastatic potential. Using the above models, they 
found that cancer cells with identical genetic background 
may develop into tumors with differential metastatic poten-
tials, since different tumor microenvironment changes the 
expression level of oncogenes related to metastasis [20].  
(v) Immunology, prevention and treatment of cancer.  
Scientists in China have made great progress in cancer im-
munotherapies. For instance, Wei YuQuan’s team proposed 
a new theory in cancer immunology, suggesting that het-
eroantigens can effectively abolish immune tolerance of 
malignant tumors, induce anti-cancer immunity, and thus 
may serve as a novel strategy for cancer immunotherapy 
[21]. Guo YaJun’s team proposed to modulate the antigen 
presenting function of cancer cells to activate tumor specific 
immune response triggered by host antigen, suggesting a 
new strategy to stimulate anti-cancer immunity by fusing 
the antigen presenting cells with tumor cells [22]. 
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Cao XueTao’s team systemically conducted basic and 
translational research on the tumor immunology, including 
the mechanism of dendritic cells (DC) and their clinical 
application as immuno-gene therapy. They creatively iden-
tified a new cluster of DCs with important immuno-modu- 
lation functions and found that matured DCs could further 
proliferate and differentiate upon stimulation by matrix. 
New approaches combined with immunotherapy and gene 
therapy, were applied both in laboratories and clinical stud-
ies [23]. Wang ZhiBiao has invented a High Intensity Fo-
cused Ultrasound (HIFU) system for cancer treatment, 
which was the first cancer treatment device with completely 
independent intellectual property rights in China [24]. 
3  Talents fostering under NSFC’s support 
NSFC has launched the Talent-Training Program with 7 
different subcategories to foster young scientists (Table 2) 
and has played an important role in scientist training at dif-
ferent levels in China. National Science Fund for Distin-
guished Young Scholars, considered as a “Top Gun Acad-
emy” in fostering young talent scientists in China, supports 
young scholars who have made outstanding achievements in 
basic research to aim at their own research directions and to 
conduct creative studies. The goals of this program are to 
speed up the independence of young scientific talents, to 
encourage homecoming of overseas talents and to foster a 
group of prominent academic pace markers in the leading 
fronts of world science and technology. In the field of med-
icine, most of the talented scientists have been supported by 
National Science Fund for Distinguished Young Scholars 
before they reach the age of 45 year and some of them have 
made tremendous progress in oncological research. Of note, 
these members of the Chinese Academy of Sciences or the 
Chinese Academy of Engineering, Wang HongYang, Shang 
YongFeng, Zeng YiXin, He FuChu, Wei YuQuan, Zhang 
XueMin, Cao XueTao, Fan DaiMin, and Zhan QiMin and 
Profs. Lin DongXin, Song ErWei, Guo YaJun, Wang 
ZhiBiao, were all funded by this program and the Key Pro-
gram of NSFC. Moreover, another Talent-Training Program 
supporting a group of scientists to perform coordinated re-
search work is also crucial to scientists in cancer research, 
and the members of the Chinese Academy of Sciences or 
the Chinese Academy of Engineering Wang HongYang, 
Cao XueTao, Fan DaiMin and Zhan QiMin are all support-
ed by this program.  
Outstanding Young Investigator Fund is another Tal-
ent-Training Program freshly established in 2012. As a sup-
plement to the program for Distinguished Young Scholars, 
this grant serves as an effective bridge to link the existing 
programs for general Young Scientists Fund and Distin-
guished Young Scholars, so as to promote the rapid growth 
of creative scientific talents in China. In 2012, a total of 98 
applications were submitted for this funding. Among which, 
9 applicants gained support, with a funding rate of 9.18%, 
reflecting a fierce competition in this field. 
In addition to high-impact research papers, the scientific 
influence of Chinese scientists on cancer research is also 
demonstrated by their increasing international academic 
status. More and more outstanding scientists are invited as 
chairs or keynote speakers in international conferences. For 
example, Cao XueTao serves as an executive committee 
member of International Union of Immunological Societies 
(IUIS), deputy chief-editor of Gene Therapy, co-chief-editor 
of Cellular and Molecular Immunology, etc. He FuChu 
serves as a co-principal investigator of the International 
Human Liver Proteome Project (HLPP), council member of 
the Human Proteome Organization (HUPO) etc. HLPP is 
the first human organ-/tissue-based proteome project, and 
the first high-impact international cooperative program pro-
ject led by a Chinese scientist, which was reported by Na-
ture, Science and Nature Biotechnology. More than 200 
manuscripts were published by He’s team in the past 10 
years in scientific journals including Science, Nature Ge-
netics, Nature Cell Biology, Nature Biotechnology, Nature 
Methods, Nature Medicine, Nature Protocol and PNAS. 
4  The role of NSFC grant(s) in the national 
funding structure 
National “973 Program”, another national funding source 
from Ministry of Science and Technology of China, also 
finances basic cancer research but mainly focuses on major 
basic scientific questions with limited supporting fields. 
Hence, “973 Program” places emphasis on only very few 
research areas, instead of the systematicness of cancer sci-
ence, and does not carry the mission of discipline develop-
ment and talent training. 
In contrast, NSFC emphasizes systematic, prospective 
and explorative cancer research fields, with special high-
lights on building up research foundation and training tal-
ented cancer scientists. Hence, the goal of NSFC funding 
support is to promote balanced development of all research 
disciplines and to speed up high-impact scientific achieve-
ments approaching international standards. Especially, var-
ious categories of NSFC programs for scientist training help 
to expand our talent reserve, to cultivate outstanding young 
scientists and to build up cooperative research groups for 
top-level cancer research in China. 
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